Editor’s Note: BioCentury’s co-founders, Chairman Karen Bernstein, Ph.D., and President & CEO David Flores, have written to the company’s employees about BioCentury’s ...
A pivotal Phase II readout for Finch’s microbiome treatment for recurrent Clostridium difficile infection paves the way for a Phase III trial that will further test the ...
While the COVID-19 testing conversation has centered on assays for antiviral antibodies or the virus itself, at least two companies think T cell tests could catch patients the ...
Citing recruitment difficulties that render trial completion unfeasible, Novartis has discontinued its hydroxychloroquine study for COVID-19. The announcement is the latest in a ...
Among the 157 COVID-19 vaccines in development, at least 18 have reached the clinic.
Sichuan Clover Biopharmaceuticals Inc. is the latest company to enter ...
As COVID-19 safety concerns and social distancing measures continue to disrupt clinical trials around the U.S., FDA has released
A trio of Democrats on the House Oversight Committee are asking FDA for more information on how the agency plans to evaluate and deploy COVID-19 vaccines, in an effort to ensure ...
Three of four life sciences IPOs priced above expectations ahead of Friday’s session, and two biotechs in the group -- Forma and Repare -- posted big gains in their first trading ...
CAR T liver fibrosis therapy
Memorial Sloan Kettering Cancer Center researchers have generated CAR T cells against PLAUR, which is involved in ...
Nurix Therapeutics Inc. has announced a slew of leadership changes including Gwenn Hansen’s promotion to CSO from SVP of research, and Hans van Houte’s promotion ...
BioCentury ISSN 1097-7201
